Shanghai Fosun Pharma may jump into the nearly $4 billion bidding war for Germany’s Stada, an established European generic drug maker; Beijing’s BeiGene is raising $330 million to build a biologic drug manufacturing facility in Guangzhou; Xynomic Pharma, a US-China oncology startup, acquired China rights to a novel ACAT-1 inhibitor for cancer from Resarci Therapeutics of the US in a $60 million deal; BeyondSpring of New York City and China completed a $54 million capital raise via a $3.5 million IPO and a $50.8 private placement; BOE Technology, a Beijing company that is China’s largest maker of crystal displays, invested $50 million in Israeli medical device company Cnoga Medical; China life science investor Frontline Bioventures closed its second RMB fund at an undisclosed size; Luqa Pharma of Shanghai signed a definitive agreement to acquire aesthetic product in-licensor Arista Pharma; XW Labs, a Wuhan novel drug company, in-licensed rights to a class of CNS and oncology molecules from the University of Pittsburgh; and Venus Medtech of Hangzhou partnered with Israel’s Keystone Heart to bring Keystone’s embolic protection device to China.
